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PKCε, an oncogenic member of the PKC family, is
aberrantly overexpressed in epithelial cancers. To
date, little is known about functional interactions of
PKCεwith other genetic alterations, as well as the ef-
fectors contributing to its tumorigenic andmetastatic
phenotype. Here, we demonstrate that PKCε cooper-
ates with the loss of the tumor suppressor Pten for
the development of prostate cancer in a mouse
model. Mechanistic analysis revealed that PKCε
overexpression and Pten loss individually and syner-
gistically upregulate the production of the chemo-
kine CXCL13, which involves the transcriptional acti-
vation of the CXCL13 gene via the non-canonical
nuclear factor kB (NF-kB) pathway. Notably, targeted
disruption of CXCL13 or its receptor, CXCR5, in pros-
tate cancer cells impaired their migratory and tumor-
igenic properties. In addition to providing evidence
for an autonomous vicious cycle driven by PKCε,
our studies identified a compelling rationale for tar-
geting the CXCL13-CXCR5 axis for prostate cancer
treatment.
INTRODUCTION
Since its identification as the main intracellular receptor for the
phorbol ester tumor promoters, protein kinase C (PKC) has
been widely implicated in cancer progression. The PKC family
of Ser/Thr kinases has been categorized into classical (cPKCs
a, bI, bII, and g), novel (nPKCs d, ε, h, and q), and atypical (aPKCs
z and l/i) groups. cPKCs and nPKCs, the phorbol-ester-regu-
lated PKCs, are physiologically activated by diacylglycerol
(DAG), a lipid second messenger generated by activation of
extracellular receptors (Griner and Kazanietz, 2007; Rosse
et al., 2010). The diverse functional specificity of individualC
This is an open access article under the CC BY-NPKC isozymes (i.e., tumor promoters versus tumor suppressors)
reflects their cell-type-specific idiosyncratic regulation of onco-
genic and growth-inhibitory signaling pathways. Altered patterns
of isozyme expression and/or activation status are often linked to
promotion or suppression of the cancer phenotype (Garg et al.,
2014; Murray et al., 2011).
Among the multiple PKCs, PKCε emerged as a pro-oncogenic
kinase and tumor biomarker. PKCε upregulation has been re-
ported in a number of cancer types, potentially reflecting its
involvement in disease etiology and progression (Aziz et al.,
2007; Griner and Kazanietz, 2007; Jain and Basu, 2014; Pan
et al., 2005). Growth-promoting, survival, and transforming roles
for PKCε have been identified in numerous cellular models.
Consistent with these effects, PKCε activatesmitogenic and sur-
vival pathways, namely Ras/Erk, phosphatidylinositol 3-kinase
(PI3K)/Akt, nuclear factor kB (NF-kB), and Stat3 (Aziz et al.,
2007; Benavides et al., 2011; Garg et al., 2014; Jain and Basu,
2014; McJilton et al., 2003; Meshki et al., 2010; Mischak et al.,
1993). PKCε also emerged as a positive regulator of cancer
cell motility, invasion, and epithelial-mesenchymal transition
(EMT) (Caino et al., 2012b; Garg et al., 2014; Jain and Basu,
2014). Accordingly, pharmacological inhibition or RNAi silencing
of PKCε impairs cancer cell growth in culture and as xeno-
grafts and prevents their metastatic dissemination (Aziz et al.,
2007; Caino et al., 2012a; Pan et al., 2005). Notwithstanding,
the molecular mechanisms and downstream effectors behind
the tumorigenic and metastatic activities of PKCε remain only
partially understood.
Emerging evidence links PKCε to prostate cancer progres-
sion. PKCε is essentially undetectable in normal or benign pros-
tate epithelium; however, it is highly expressed in most human
prostate tumors and recurrent disease (Aziz et al., 2007; Corn-
ford et al., 1999; McJilton et al., 2003). Spontaneous prostate tu-
mors formed in TRAMPmice, and their metastases are impaired
upon genetic ablation of the PKCε gene (Prkce) (Hafeez et al.,
2011). Notably, transgenic overexpression of PKCε in the mouse
prostate leads to preneoplastic lesions; however, it is insufficient
to confer a complete cancer phenotype (Benavides et al., 2011).ell Reports 19, 375–388, April 11, 2017 ª 2017 The Author(s). 375
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The nature of PKCε effectors responsible for the acquired pros-
tate phenotype and the functional interaction with relevant onco-
genic/tumor suppressing inputs remain poorly understood.
PI3K is another pathway widely implicated in the progression
of prostate cancer. PIK3CA gene amplification and mutations
can be detected in advanced prostate tumors (Agell et al.,
2011; Robinson et al., 2015; Sarker et al., 2009; Sun et al.,
2009). However, the most common alteration in this pathway is
the loss of PTEN, a phosphatase for the PI3K product PIP3.
PTEN gene deletions and inactivating mutations are commonly
observed in prostate tumors and their metastases (Sarker
et al., 2009). Not surprisingly, loss of a single Pten allele confers
preneoplastic lesions, whereas conditional deletion of both Pten
alleles leads to metastatic prostate cancer (Blando et al., 2011;
Di Cristofano et al., 1998; Kim et al., 2002; Podsypanina et al.,
1999; Zhong et al., 2006). Here, we report that PKCε overexpres-
sion and Pten loss functionally interact for the development of
prostate cancer in amousemodel, andwe identified C-X-Cmotif
chemokine 13 (CXCL13) as a bona fide effector of PKCε in pros-
tate cancer, thus establishing a molecular paradigm in the pro-
gression of this disease.
RESULTS
PKCε Overexpression Cooperates with Pten Loss to
Promote Prostate Cancer
Prostate-specific overexpression of PKCε in mice under the
control of rat probasin (PB) promoter (PB-PKCε) confers pros-
tatic intraepithelial neoplasia (PIN) lesions that do not progress
to malignancy (Benavides et al., 2011). As PTEN loss of function
is a frequent event in human prostate cancer, we intercrossed
our transgenic PB-PKCε mice with mice heterozygous for Pten
(Pten+/), which also display prostate preneoplastic lesions
(Blando et al., 2011; Di Cristofano et al., 1998; Zhong et al.,
2006). Remarkably, in addition to hyperplasia and PIN lesions,
the resulting compound mutant mice (PB-PKCε;Pten+/) devel-
oped well-differentiated prostatic adenocarcinomas (ACs), pref-
erentially in the ventral prostate, with an incidence of 64% at
12 months (Figures 1A and 1B). No other lesions could be de-
tected in the remaining of the genito-urinary track. ACs in PB-
PKCε;Pten+/ mice display tubule and acinar structures and
show in some cases evident stromal invasion (Figure S1A). PIN
lesions in the compound mice presented cribriform patterns;
cells display karyomegaly and cytomegaly and an enlarged nu-
cleus with apical localization, and two or more macro-nucleoli
were also observed. ACs showed the presence of macro-
nucleoli, nucleus with enlarged shapes, and evident neovascula-
rization. Thus, PKCε overexpression and Pten loss cooperate for
the development of prostate cancer in mice. In line with these
findings, Kaplan-Meier and Cox univariate regression analyses
using the Cancer Genome Atlas (TCGA) RNA-sequencing
(RNA-seq) dataset obtained from the Cancer Genomics Browser
(https://genome-cancer.soe.ucsc.edu) show the worst prog-
nosis for prostate cancer patients with high PKCε and low
PTEN levels (Figure S1B).
As previously observed (Benavides et al., 2011), immunohisto-
chemical analysis of PINs from PB-PKCε mice revealed activa-
tion of Akt and its effectors mTOR and S6. A similar effect376 Cell Reports 19, 375–388, April 11, 2017was seen in PINs from Pten+/ mice. Prostatic ACs in PB-
PKCε;Pten+/ compound mice display stronger staining for
these markers (Figure 1C). Consistent with the role of PKCε in
Stat3 activation in prostate cancer (Aziz et al., 2007; Hafeez
et al., 2011), significant phospho-Stat3 staining was observed
in PIN lesions and ACs, particularly in the nucleus.
Cooperation of PKCε Overexpression and Pten Loss for
Growth and Tumorigenesis
To assess the mechanisms underlying the observed cooperati-
vity between PKCε overexpression and Pten loss in prostate
cancer, we took advantage of isogenic murine prostate epithelial
cell lines derived from Pten knockout (KO) mice that either ex-
press (P2 and P8) or do not express Pten (CaP2 and CaP8)
(Jiao et al., 2007). Cells were stably transduced with lentiviruses
for either PKCε or LacZ (LZ; control) (Figure 2A). P2 and P8 cells
overexpressing PKCε (P2-PKCε and P8-PKCε) proliferate at
higher rates than the corresponding control cell lines (P2-LZ
and P8-LZ), while CaP2 and CaP8 cells displayed slightly
elevated proliferation rates. A large proliferative advantage was
observed in Pten null cells subject to PKCε overexpression
(CaP2-PKCε and CaP8-PKCε), which became particularly
evident in clonogenic and anchorage-independent growth as-
says (Figures 2B, 2C, and S2A). Remarkably, only CaP8-PKCε
cells display tumorigenic activity upon subcutaneous (s.c.) inoc-
ulation into nude mice (Figure 2D). A bulbous hyperplastic over-
growth was observed for CaP8 and P8-PKCε cells; however,
these cell lines did not form tumors in nude mice.
Next, we assessed the effect of PKCε overexpression on rele-
vant proliferation and survival signaling pathways. Consistent
with our previous findings in ‘‘normal’’ immortalized human
RWPE1 prostate epithelial cells (Benavides et al., 2011), PKCε
overexpression in P8 cells led to a small increase in basal and
epidermal growth factor (EGF)-stimulated phospho-Erk, phos-
pho-Akt, and phospho-mTOR levels. Most notably, CaP8-
PKCε cells displayed higher basal as well as EGF-stimulated
activation of Erk, Akt, and mTOR (Figure 2E). Platelet-derived
growth factor (PDGF) and insulin growth factor 1 (IGF-1) stimula-
tion led to comparable effects (Figure S2B). Taken together,
these results indicate a strong cooperativity between PKCε over-
expression and Pten loss for growth/survival signaling and
tumorigenesis.
PKCε Overexpression Promotes Migratory and Invasive
Phenotypes
Emerging evidence linked PKCε with cancer cell migration and
invasiveness in vitro and in vivo (Garg et al., 2014). We found
that migration of P8-PKCε and CaP8 cells in response to fetal
bovine serum (FBS), IGF-1, or PDGF was significantly higher
than parental P8 cells, as assessed with a Boyden chamber.
Interestingly, a remarkably high migratory response to stimuli
was observed in CaP8-PKCε cells (Figure 2F), which was also
evident in wound assays (Figure S3). Assessment of the invasive
properties revealed similar results, with CaP8-PKCε cells dis-
playing the strongest invasive potential (Figure 2G). Hence, over-
expression of PKCε in a Pten null background caused a dramatic
enhancement in migratory and invading capabilities of prostate
epithelial cells.
Figure 1. Phenotypes of Male PB-PKCε and
PB-PKCε;Pten+/ Mice
(A) H&E staining in ventral prostates from
12-month-old normal wild-type mice (a) and
PB-PKCε;Pten+/ mice (b–i). Magnification 203,
unless otherwise indicated. Scale bar, 100 mm.
(B) Incidence of lesions in 12-month-old mice.
(C) Immunohistochemical analysis of signaling
markers. Scale bar, 100 mm.Transcriptome Analysis of PKCε-Overexpressing Cells
To search for the molecular mechanisms underlying the
observed phenotypes, a global gene expression profiling wasCecarried out. Using the rank product test
(q-value < 0.05), we identified 898, 573,
and 1,101 differentially expressed genes
associated with PKCε overexpression,
Pten loss, and both alterations together,
respectively, with some degree of overlap
(Figure 3A; full list in Table S1). This
analysis also revealed 187 genes (86 up-
regulated and 101 downregulated) that
were commonly altered in CaP8, P8-
PKCε, and CaP8-PKCε cells (Figures
S4A–S4C). The top upregulated can-
didate among the differentially ex-
pressed genes categorized in CaP8-
PKCε versus P8 group was CXCL13
(fold change = 5.5, q < 0.0001), the gene
coding for C-X-C motif chemokine 13.
CXCL13 was also among the top
upregulated genes in P8-PKCε (fold
change = 3.8, q < 0.0001) and CaP8 cells
(fold change=2.9, q< 0.0001) (Figure 3B).
Other prostate-cancer-related genes that
were commonly deregulated in the three
genetic backgrounds include ITGB8,
LGR4, GPNMB, and MMP2.
Analysis usingGeneOntology (GO) and
Kyoto Encyclopedia of Genes and Ge-
nomes (KEGG) databases uncovered
major changes in pathways involved in
cell proliferation, migration, adhesion,
angiogenesis, and metabolism (Fig-
ure 3C). Comparison of biological pro-
cesses enriched among the three cell
lines depicts not only significant overlap-
ping but also unique pathways ensuing
PKCε overexpression and Pten loss (Fig-
ure 3D). An additional analysis of the
top 50 deregulated transcripts (FC > 2,
q-values < 0.000001) using Cytoscape
and CluePedia identified a network of
functionally enriched KEGG pathways
specifically pertaining to PI3K-Akt
signaling, GPCR-ligand binding, extra-
cellular matrix organization, and cyto-kine-cytokine receptor interaction (Figure 3E). A comparative
analysis of CaP8-PKCε-associated genes with the GSE6919
database identified 189 genes commonly deregulated betweenll Reports 19, 375–388, April 11, 2017 377
Figure 2. PKCε Overexpression and Pten Deletion Cooperate for Growth, Motility, and Invasion
(A) PKCε overexpression in P2, P8, CaP2, and CaP8 cells was achieved with a PKCε lentivirus. Control cells were infected with a LacZ (LZ) lentivirus.
(B) Clonogenic assay. Colony formation was assessed 15 days after cell seeding. Left: representative experiment. Right: quantification of colonies per plate.
(C) Anchorage-independent growth in soft agar was determined 21 days after seeding. Left: representative experiment. Right: quantification of colonies per field
(five independent fields were counted and averaged).
(D) Tumor formation inathymicnudemice. Left: representativepictures35daysafter s.c. inoculation.Right: Tumor volume, expressedasmean±SD (n=5mice/group).
(E) Activation of Akt, Erk, and mTOR in response to EGF (3 ng/mL, 2 min) as determined by western blot.
(F) Migration in the Boyden chamber in response to FBS (5%), IGF (50 ng/mL), or PDGF (50 ng/mL) was determined 16 hr after seeding. Left: representative
images. Right: quantification of migrating cells by contrast microscopy in five independent fields. Results are expressed as mean ± SD of triplicate measure-
ments. Two experiments gave similar results.
(G) Invasion was determined as in (F) but with Matrigel.
In (B)–(G), *p < 0.05 and **p < 0.01.
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Figure 3. Gene Expression Profiling of PKCε-Overexpressing Prostate Epithelial Cells
(A) Heatmap of deregulated genes in murine cellular models. Red and green lines on the right indicate genes up- or down-modulated, respectively, in human
primary and metastatic prostate tumors.
(B) Top 20 up-modulated genes among murine cell lines.
(C) Functional enrichment analysis of differentially expressed genes across the different cell models.
(D) Comparative analysis of enriched biological pathways/functions.
(E) CluePedia network of functionally enriched pathways and genes differentially expressed in CaP8-PKCε versus P8 cells.
(F) Euler diagram of transcripts commonly expressed among murine cell lines and human prostate cancer (GSE6919 dataset).
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Figure 4. Association between PKCε and CXCL13 in Prostate Cancer
(A) Functional association among PKCε, Pten, CXCL13, and CXCR5 based on co-expression, physical interaction, pathways and co-localization data, using
GeneMania.
(B) Kaplan-Meier analysis was performed among 365 patients with prostate carcinomas obtained from the TCGA-PRAD project. Patients were grouped as 82
with low PRKCE/CXCL13/CXCR5, 107 with low PRKCE-high CXCL13/CXCR5, 92 with high PRKCE-low CXCL13/CXCR5, and 84 with high PRKCE/CXCL13/
CXCR5. p value is reported for curves (marked with #).
(legend continued on next page)
380 Cell Reports 19, 375–388, April 11, 2017
this cell line and primary prostate carcinomas and/or metastatic
samples, as shown in the Euler diagram in Figure 3F (see also
Figure 3A; list of genes in Table S2). Among these genes, 140
were associated with prostate tumor metastases, 35 with pri-
mary tumors, and 14 with primary and metastatic prostate
samples. Thus, striking similarities in the pattern of gene expres-
sion exist between the murine CaP8-PKCε genotype and that
observed in human prostate cancer metastasis (Figure S4D).
PKCε Regulates CXCL13 Expression in Prostate Cancer
Cells
As indicated above, the top hit from our microarray analysis in
CaP8-PKCε cells was CXCL13. The chemokine CXCL13 (origi-
nally known as B cell chemoattractant, BCL) and its receptor,
the GPCR C-X-C motif receptor 5 (CXCR5), emerged as pivotal
players in the progression of many cancers (Airoldi et al., 2008;
Biswas et al., 2014; Sambandam et al., 2013), including prostate
cancer (Ammirante et al., 2014; El Haibi et al., 2010; Singh et al.,
2009a, 2009b). Enhanced CXCR5 expression and hyperactiva-
tion of CXCR5 effectors occur in prostate cancer, and serum
CXCL13 levels have been postulated as a biomarker of prostate
cancer progression (Singh et al., 2009a, 2009b). A significant
correlation between CXCL13 and CXCR5 expression occurs
in human prostate cancer (Figure S4E). Further, a pathway re-
construction approach using GeneMania revealed CXCR5 as
a gene functionally related with PRKCE, PTEN, and CXCL13
based on co-expression and physical interaction (Figure 4A).
Kaplan-Meier analysis revealed the shortest recurrence-free sur-
vival specifically in patients categorized as high PRKCE/high
CXCL13-CXCR5 (Figure 4B).
As expected from the microarray data (Figure 4C, left panel),
qPCR validation showed a clear elevation inCxcl13mRNA levels
in P8-PKCε and CaP8 cells relative to P8 cells (13- and 9-fold,
respectively) and a striking 40-fold upregulation in CaP8-
PKCε cells (Figure 4C, middle panel). When CXCL13 protein
levels were determined in the culture media by ELISA, a similar
trend was observed (Figure 4C, right panel). Upregulation of
CXCL13 mRNA levels was found in established human prostate
cancer cells relative to non-transformed RWPE-1 cells (Fig-
ure 4D, left panel). Accordingly, CXCL13 protein release was
higher in prostate cancer cell lines, particularly in aggressive
androgen-independent cell lines (Figure 4D, right panel), which(C) CXCL13 expression in prostate epithelial cell lines. Left: CXCL13mRNA expres
CXCL13 protein levels in the culture media by ELISA. Results normalized to P8
ELISA, two experiments gave similar results.
(D) Left: CXCL13 mRNA levels in human prostate cancer cells. Right: CXCL13 pro
as mean ± SD of triplicate measurements.
(E) P8 cells were infected with differentMOIs of PKCε or LacZ AdV (LZ, control) for
in culture media assessed by ELISA 16 hr after infection. Bottom: PKCε levels de
relative to LZ.
(F) PC3 and DU145 cells were transfected with RNAi duplexes for PKCε (ε1 and
levels determined by qPCR. Right: CXCL13 protein levels in culturemedia assesse
Results are normalized to NTC transfected cells.
(G) CXCL13 serum levels in mice by ELISA.
(H) CXCR5 expression in human prostate cancer cells by western blot.
(I) CXCR5 expression in murine cells by western blot.
(J) CXCR5 levels in murine cells by flow cytometry. Left and middle: representat
In (C)–(F) *p < 0.05 and **p < 0.01.also express high PKCε levels (Benavides et al., 2011; Garg
et al., 2012).
A causal relationship between PKCε levels andCXCL13 induc-
tion was observed in P8 cells in which PKCε was overexpressed
using an adenovirus (AdV) (Figure 4E). In addition, silencing
PKCε expression from PC3 and DU145 prostate cancer cells
considerably reduced CXCL13 mRNA and secreted protein
levels (Figure 4F). Interestingly, we observed a significant
elevation in serum CXCL13 levels in PKCε transgenic mice,
particularly in PB-PKCε;Pten+/ mice (Figure 4G). Together,
these observations argue for a stringent regulation of CXCL13
expression by PKCε in prostate cancer.
CXCR5, the CXCL13 receptor, is overexpressed in prostate
tumors (Singh et al., 2009b). Consistent with this, prostate can-
cer cell lines display higher CXCR5 levels than RWPE1 cells (Fig-
ure 4H). However, we could not find appreciable differences in
CXCR5 expression among P8, P8-PKCε, CaP8, and CaP8-
PKCε cells (Figure 4I). Considering that each cell line is exposed
to different CXCL13 levels in the medium, which may lead to re-
ceptor internalization, we next asked if changes in surface
CXCR5 expression occur. Still, there were no significant differ-
ences among the murine cell lines, both in surface and total
CXCR5 receptor levels (Figure 4J). Therefore, although PKCε
overexpression and Pten loss are causally linked to the
CXCL13 induction, they do not seem to influence CXCR5
expression.
An Autocrine CXCL13-CXCR5 Loop Mediates Migration
Driven by PKCε Overexpression and Pten Loss
Next, we wished to test if the enhanced production of CXCL13
contributes to PKCε-driven phenotypes. We first assessed the
activity of conditioned media (CM) collected from PKCε-over-
expressing and/or Pten-depleted prostate epithelial cells.
CXCL13 levels in the medium peak at 16 hr following cell
seeding (Figure S5A). Conditioned media from P8, P8-PKCε,
CaP8, and CaP8-PKCε cells was therefore collected at 16 hr
and assessed for their ‘‘pro-migratory’’ activity when added
to naive P8 cells. The ranking of activity of the different condi-
tioned media was CM-CaP8-PKCε > CM-P8-PKCε > CM-
CaP8 > CM-P8 cells (Figure 5A), which is in concurrence
with the gradation of CXCL13 production from each cell line
(see Figure 4C).sion frommicroarray data. Middle: CXCL13mRNA expression by qPCR. Right:
cells are expressed as mean ± SD of triplicate measurements. For qPCR and
tein levels in culture media. Results normalized to RWPE-1 cells are expressed
24 hr. Top left: CXCL13mRNA levels by qPCR. Top right: CXCL13 protein levels
termined by qPCR and western blot. Results were expressed as fold-increase
ε2) or a non-target control (NTC) RNAi. P, parental cells. Left: CXCL13 mRNA
d by ELISA 16 hr after transfection. Western blot for PKCε expression is shown.
ive experiments. Right: quantification expressed as mean ± SD.
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Figure 5. PKCε Overexpression and Pten Loss Induce Migration through an Autocrine CXCL13-CXCR5 Loop
(A) P8 cells were treated with conditioned medium from P8, P8-PKCε, CaP8, or CaP8-PKCε cells and migration assessed using a Boyden chamber. Left:
experimental scheme. Middle: representative images. Right: quantification of migrating cells by contrast microscopy in five independent fields. Results are
expressed as mean ± SD of triplicate measurements. Two experiments gave similar results.
(B) Conditioned medium was collected from CaP8-PKCε cells subject to either CXCL13 or non-target control (NTC) RNAi. Left: CXCL13 mRNA levels in CaP8-
PKCε cells (qPCR) and protein levels in CM-CaP8-PKCε cells (ELISA). Results normalized to NTCwere expressed asmean ± SD (n = 3). Middle: P8 cell migration
was determined after treatment with conditioned medium from CaP8-PKCε cells subject to either CXCL13 or NTC RNAi. Reconstitution with recombinant
CXCL13 (100 ng/mL) added to the conditioned medium was done where indicated. Right: quantification of migrating cells.
(C) P8 cells subjected to either CXCR5 or NTC RNAi were treated with conditioned medium collected from CaP8-PKCε cells. Left: CXCR5 mRNA levels in P8
(recipient) cells were determined by qPCR. Results normalized to NTCwere expressed as mean ± SD (n = 3). Middle: representative images. Right: quantification
of migrating cells.
(legend continued on next page)
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To determine if this pro-migratory effect is causally related
to the released CXCL13, CaP8-PKCε cells were subject to
CXCL13 RNAi depletion, which as expected reduced CXCL13
mRNA levels and protein release (Figure 5B, left panel, and Fig-
ure S5B). Notably, conditioned medium from CXCL13-depleted
CaP8-PKCε cells significantly lost its ability to induce amigratory
response when added to naive P8, P8-PKCε, or CaP8 cells. This
effectwas rescued by exogenous addition ofCXCL13 (Figure 5B,
middle and right panels, and Figures S5C–S5E). In addition,
when CXCR5 expression in the recipient naive P8 cells was
silenced, the pro-migratory activity of CM-CaP8-PKCε was
essentially lost (Figures 5C and S5F), thus hinting at the impor-
tant role of CXCL13 in this context.
To confirm the functional relevance of the enhanced CXCL13
production via an autocrine loop, we used three additional ap-
proaches. First, CXCL13 RNAi abrogated the migratory activity
of CaP8-PKCε cells (Figures 5D and S5G). Second, a neutralizing
anti-murine CXCL13 antibody dose-dependently inhibited migra-
tion of CaP8-PKCε cells compared to a non-specific isotype con-
trol antibody (Figure 5E). Lastly, silencing CXCR5 expression from
PKCε-overexpressing and/or Pten-depleted cells markedly in-
hibited their migratory activities (Figure 5F). Similar experiments
in human PC3 cells showed that CXCL13 RNAi, which depleted
CXCL13 mRNA levels and protein release, markedly impaired
migration, an effect rescued by the addition of recombinant
CXCL13 (Figure 5G). Similarly, PC3 cell migration was inhibited
by theadditionof aneutralizinganti-humanCXCL13antibody (Fig-
ure 5H) or CXCR5 silencing (Figure 5I). Taken together, these
results demonstrate a fundamental role of the CXCL13-CXCR5
autocrine axis in driving prostate cancer cell migration.
TheCXCL13-CXCR5Axis Contributes to theGrowth and
Tumorigenicity of Prostate Cancer Cells
Next, we aimed to determine if the CXCL13-CXCR5 pathway
was involved in growth driven by PKCε overexpression. To
address this issue, we first used CXCR5-depleted murine cell
lines (shown in Figure 5F). CaP8-PKCε cells, which display the
highest growth in culture (see Figures 2 and S2), significantly
reduced their proliferative capacity uponCXCR5RNAi depletion.
A comparable inhibitory effect of CXCR5 RNAi was observed in
P8-PKCε andCaP8 cells (Figure 6A). Stable CXCR5 andCXCL13
depletion from CaP8-PKCε cells using small hairpin RNA
(shRNA) lentiviruses also impaired their ability to form colonies
in soft agar (Figures 6B and S6) as well as tumorigenic capacity
in nude mice (Figure 6C).(D) Migration of CaP8-PKCε cells subject to either CXCL13 or NTC RNAi. Left: re
(E) Migration of CaP8-PKCε cells incubated with either a neutralizing anti-murine
images. Right panel: quantification of migrating cells.
(F) P8, P8-PKCε, CaP8, and CaP8-PKCε cells were infected with either CXCR5 or
in a Boyden chamber. Left: CXCR5 expression by western blot. Middle: represe
(G) Effect of CXCL13 or NTC RNAi on PC3 cell migration. Left: CXCL13 mRNA lev
NTC were expressed as mean ± SD (n = 3). Middle: representative experiment.
tification of migrating cells.
(H) Migration of PC3 cells incubated with either a neutralizing anti-human CXCL13
quantification of migrating cells.
(I) PC3 cells were infected with different CXCR5 or NTC shRNA lentiviruses, follow
representative images. Right: quantification of migrating cells.
In (A)–(I) *p < 0.05 and **p < 0.01.Next, we extended our growth and tumorigenicity studies to
human PC3 cells subject to stable CXCR5 RNAi depletion (see
Figure 5I). We found that CXCR5 was required for the growth
of PC3 cells in soft agar and nudemice (Figures 6D and 6E). Alto-
gether, our findings underscore the requirement of the autocrine
CXCR5-CXCL13 axis in growth and tumorigenic activity of pros-
tate cancer cells.
CXCL13 Upregulation Is Mediated by the Non-canonical
NF-kB Pathway
To dissect the mechanisms governing CXCL13 upregulation by
PKCε overexpression and Pten loss, we first used inhibitors of
various signaling pathways. As expected, the PKC inhibitor
GF109203X and the PI3K inhibitor BKM120 significantly reduced
CXCL13 mRNA levels and protein release from CaP8-PKCε
and PC3 cells. BX795, an inhibitor of PDK1, a PI3K-dependent
kinase acting upstream of PKCs, had no effect on CXCL13
levels. Interestingly, CXCL13 expression and release were abro-
gated by NF-kB inhibitors IkB kinase (IKK)16 and wedelolactone
(Figures 7A and S7).
PKCε activation significantly impacts the transcriptional regu-
lation of genes (Garg et al., 2013). We therefore focused on tran-
scriptional activation of the CXCL13 gene using a CXCL13 pro-
moter luciferase reporter assay. Notably, P8-PKCε and CaP8
cells display enhanced CXCL13 reporter activity relative to P8
cells. This effect was even larger in CaP8-PKCε cells (Figure 7B).
Interestingly, the CXCL13 reporter activity in CaP8-PKCε cells
was sensitive to PKC, PI3K, and NF-kB, but not PDK1, inhibition
(Figure 7C).
NF-kB is a known effector of PKCε and PI3K pathways
(Fernandez-Marcos et al., 2009; Garg et al., 2012). Silencing
key elements of the NF-kB pathway, IKKa and IKKb, in CaP8-
PKCε cells led to 84% and 31% inhibition in CXCL13
mRNA levels, respectively. As IKKa signals preferentially toward
the non-canonical NF-kB pathway, we assessed the effect of
knocking down NF-kB inducing kinase (NIK), a kinase associ-
ated with IKKa in this cascade. Remarkably, similar to IKKa
RNAi, NIK RNAi abolished CXCL13 mRNA expression as well
as transcriptional activation of the CXCL13 gene (Figures 7D
and 7E). In silico analysis of the CXCL13 promoter identified a
putative non-canonical NF-kB site that has also been previously
characterized (Bonizzi et al., 2004) as well as putative sites for
previously described responsive elements regulated by PKCε,
specifically octamer-binding transcription factor 1 (OCT1) and
hepatocyte nuclear factor 1 (HNF-1) (Garg et al., 2013). Uponpresentative images. Right: quantification of migrating cells.
CXCL13 or a non-specific isotype control antibody. Left panel: representative
NTC shRNA lentiviruses, selected with puromycin and their migration assessed
ntative images. Right: quantification of migrating cells.
els (qPCR) and protein release (ELISA) were determined. Results normalized to
Reconstitution with recombinant CXCL13 (100 ng/mL) is shown. Right: quan-
or a non-specific isotype control antibody. Left: representative images. Right:
ed by puromycin selection. Left: western blot for CXCR5 expression. Middle:
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Figure 6. The CXCL13-CXCR5 Axis Mediates Tumorigenesis of Prostate Cancer Cells
(A) Proliferation of P8, P8-PKCε, CaP8, and CaP8-PKCε cells infected with either CXCR5 or NTC shRNA lentiviruses.
(B) Anchorage-independent growth in soft agar. Top: representative experiment. Bottom left: quantification of colonies/field. Bottom right: western blot for
CXCR5 expression.
(C) CaP8-PKCε cells were infected with CXCR5, CXCL13 or NTC shRNA lentiviruses and selected with puromycin. Left: representative pictures of nude mice
35 days after s.c. inoculation. Right: tumor volume, expressed as mean ± SD (n = 5 mice/group).
(D) Growth in soft agar of CXCR5 stably depleted PC3 cells. Left: representative experiment. Right: quantification of colonies per field.
(E) Effect of CXCR5 silencing on PC3 tumor growth. Left: representative pictures of nudemice (day 35). Right: tumor volume, expressed asmean ±SD (n = 5mice/
group).
In (A)–(E) *p < 0.05.mutation of each of these elements, we observed that only the
NF-kB responsive element was required for CXCL13 reporter ac-
tivity in CaP8-PKCε cells (Figure 7F). Overall, these results estab-
lish a prominent role for the non-canonical NF-kB pathway in the
upregulation of CXCL13 driven by PKCε overexpression and
Pten loss via a transcriptional mechanism.
DISCUSSION
Cooperativity between PKCε Overexpression and Pten
Deficiency in Prostate Cancer
Our study provides evidence that PKCε overexpression contrib-
utes in conjunction with Pten deficiency to the development of384 Cell Reports 19, 375–388, April 11, 2017prostate cancer. PKCε overexpression is a signature of many
epithelial cancers and has been widely associated with cancer
progression, including prostate cancer (Aziz et al., 2007; Garg
et al., 2014). Prostate-specific transgenic overexpression of
PKCε in mice confers a preneoplastic phenotype and hyperacti-
vation of pro-survival pathways (Benavides et al., 2011; Garg
et al., 2014). The appearance of invasive prostatic ACs in PB-
PKCε;Pten+/ compound mice underscores the cooperative
effect of PKCε with other common disease alterations (Blando
et al., 2011; Carver et al., 2009; Zhong et al., 2006). Pten loss
leads to PI3K/Akt activation and castration-resistant growth in
mice (Mulholland et al., 2011). Likewise, mouse transgenic over-
expression of PKCε protects against apoptosis in response to
Figure 7. The NF-kB Non-canonical Pathway Mediates Transcriptional Activation of the CXCL13 Promoter
(A) Effect of GFX (0.5 mM), IKK16 (5 mM), wedelolactone (10 mM), BX795 (5 mM), and BKM120 (0.3 mM) on CXCL13 expression in CaP8-PKCε cells. Left: mRNA
levels. Right: protein levels in the culture media.
(B) CXCL13 promoter luciferase reporter activity in murine prostate cells.
(C) Effect of inhibitors on CXCL13 promoter activity in CaP8-PKCε cells.
(D) IKKa, IKKb, and NIK RNAi depletion by western blot.
(E) Effect of IKKa, IKKb, and NIK RNAi depletion. Left: CXCL13 mRNA expression. Right: CXCL13 promoter activity.
(F) Effect of mutations in responsive elements on CXCL13 promoter activity.
(G) Model: the CXCL13-CXCR5 axis as an effector of PKCε overexpression and Pten loss.
In (A)–(C), (E), and (F), *p < 0.05 and **p < 0.01.androgen ablation, which is consistent with previously estab-
lished PKCε roles in the activation of pro-survival pathways
(Aziz et al., 2007; Garg et al., 2014; Griner and Kazanietz,
2007; Jain and Basu, 2014). PKCε overexpression also contrib-
utes to tumorigenesis by conferring enhanced growth via Erk
(Benavides et al., 2011), an effect that is potentiated in the
context of PTEN deficiency. The aggressiveness of the prostate
ACs originated in PB-PKCε;Pten+/ mice may highlight addi-
tional functions, such as genomic instability and accumulation
of secondary mutations common upon Pten loss (Hubbard
et al., 2016) or facilitation of EMT due to PKCε overexpression
(Jain and Basu, 2014).Despite the similar gross pathology of prostatic lesions from
PB-PKCε and Pten+/ mice, our microarray analysis revealed
both common and distinctive genetic signatures for PKCε
overexpression and/or Pten deficiency. A similar scenario has
been described upon comparison of PIN lesions induced by
p110b, activated Akt and Pten deficiency (Lee et al., 2010).
Most remarkably, as revealed by our GO analysis, cells
displaying both PKCε overexpression and Pten loss, which
acquire tumorigenic and highly migratory/invasive properties,
are selectively enriched in a number of processes related to
tumorigenesis and metastasis. Crucial roles for PKCε have
been established in cancer cell migration and invasion. ForCell Reports 19, 375–388, April 11, 2017 385
example, PKCε-depleted lung cancer cells have impaired Rac-
dependent cell motility, invasion, andmetastatic capacity (Caino
et al., 2012b). PKCε promotes the secretion of pro-invasive fac-
tors and matrix metalloproteases (MMPs) and has been impli-
cated in the formation of invadopodial-like structures (Gutier-
rez-Uzquiza et al., 2015; Tachado et al., 2002). One scenario
currently under investigation in our laboratory is that Pten loss
leads to a hyperactivated PKCε status, as indicated by the
enhanced membrane-associated PKCε in Pten-depleted cells
(data not shown). Not surprisingly, expression of a constitutively
active PKCε mutant enhances growth and invasiveness (Garc-
zarczyk et al., 2009). A PKCε hyperactive status is likely the result
of excessive inputs, ultimately contributing to the tumorigenic
and metastatic phenotype, which seem to be independent of
the upstream PKC kinase PDK1.
The CXCL13-CXCR5 Axis as a Mediator of PKCε-Driven
Phenotypes
We identifiedCxcl13 as a gene induced by PKCε overexpression
and Pten loss in a cooperative manner. Emerging information as-
signed crucial roles to the CXCL13-CXCR5 axis in the progres-
sion of various epithelial cancers, and studies found that
CXCL13 can be produced by tumor cells (Airoldi et al., 2008; Am-
mirante et al., 2014; Biswas et al., 2014; Gaulard and de Leval,
2011; Sambandam et al., 2013). Interestingly, serum CXCL13
levels positively correlate with prostate cancer progression in
patients, and we found accordingly elevated serum CXCL13
levels in PB-PKCε;Pten+/ mice. CXCR5 signals through Erk,
PI3K, and Rac in prostate cancer cells leading to proliferative
and migratory/invasive phenotypes and couples to Ga subunits
that activate phospholipase C, the enzyme responsible for DAG
generation, the endogenous activator of PKCε (El Haibi et al.,
2010, 2011, 2013; Singh et al., 2009a, 2009b). PKCε and PI3K
activation due to Pten loss promotes CXCL13 production and
release, thus contributing to CXCR5 signal amplification and ul-
timately resulting in an autocrine tumorigenic/metastatic vicious
cycle. Consistent with this model (Figure 7G), the proliferative
and motile capacities of CaP8-PKCε and PC3 prostate cancer
cells, which express high PKCε levels and are Pten deficient,
are impaired upon disruption of the CXCL13-CXCR5 axis.
One interesting observation in this study is the identification of
the non-canonical NF-kB pathway as a converging point for sig-
nals from PKCε overexpression and Pten loss. Indeed, inter-
fering with NIK-IKKa impaired CXCL13 induction. Based on the
established role of this pathway in transcriptional activation
and its proposed relevance in prostate cancer (Garg et al.,
2014; Holley et al., 2010; Lessard et al., 2005), we focused our
attention on the CXCL13 promoter, which contains a well-
defined binding site for RelB/p52 (Bonizzi et al., 2004). Notably,
disruption of this responsive element in the CXCL13 promoter
reduced transcriptional activation in cells subject to PKCε over-
expression and Pten loss. We also found that mitogen-activated
protein kinase kinase (MEK) and Akt inhibitors reduce CXCL13
expression and transcriptional activation (data not shown),
suggesting the possibility of these kinases as required down-
stream effectors or acting as parallel mechanisms. It is worth
mentioning that the canonical NF-kB pathway has been impli-
cated in prostate cancer progression driven by PTEN and Par4386 Cell Reports 19, 375–388, April 11, 2017loss (Fernandez-Marcos et al., 2009). Data from our laboratory
also suggest that PKCε activates genes regulated by the canon-
ical NF-kB pathway (Garg et al., 2012), also in cooperation with
Pten loss (data not shown).
In addition to the cell-autonomous autocrine loop described
above, stromal cells in prostate tumors, specifically cancer-
associated myofibroblasts, produce CXCL13, leading to B cell
recruitment and castration-resistant prostate cancer (Ammirante
et al., 2014). Therefore, CXCL13 produced by both cancer and
stromal cells creates a pro-tumorigenic environment. An addi-
tional consideration is that CXCR5, which is elevated in prostate
cancer cells, may be implicated in site-specific metastasis.
Conceivably, CXCL13 produced in the bone microenvironment
may contribute to attracting prostate cancer cells to this
preferred site for prostate cancer cell metastasis (Sambandam
et al., 2013). CXCL13 is known to increase the expression of
various mesenchymal markers and MMPs, therefore enhancing
invasive capacity, and the expression of receptor activator of
nuclear factor kappa-B ligand (RANKL), a driver for castration-
resistant prostate cancer and skeletal metastasis (Biswas
et al., 2014; Sambandam et al., 2013). Therefore, an attractive
possibility is that targeting the CXCL13-CXCR5 pathway could
represent a beneficial therapeutic approach for the treatment
of advanced prostate cancer patients.
EXPERIMENTAL PROCEDURES
Reagents
CXCL13, IGF-1, and PDGF were purchased from R&D Systems. EGF was pro-
cured from BD Biosciences. Blasticidin and bovine pituitary extract were ob-
tained from Life Technologies. Insulin was purchased from Sigma-Aldrich.
Cell Culture and Western Blot
Culture of human prostate cells and western blot are described elsewhere
(Benavides et al., 2011; Garg et al., 2012). For more information about the
antibodies used, see Supplemental Experimental Procedures. Murine P8/
CaP8 prostate epithelial cells were kindly provided by Dr. Hong Wu (UCLA)
(Jiao et al., 2007).
Generation of Mouse Models, Histopathology, and
Immunohistochemistry
The generation of PB-PKCε transgenic mice in pure FVB/N background (co-
isogenic line) is described elsewhere (Benavides et al., 2011). Crossing of
PB-PKCε with Pten+/ mice, phenotypic analysis, and immunohistochemistry
(IHC) procedures are described in Supplemental Experimental Procedures.
qPCR, RNAi, Flow Cytometry, Generation of PKCε-Overexpressing
Cells, and CXCL13 Promoter Analysis
Detailed procedures are described in Supplemental Experimental Procedures.
CXCL13 ELISA Measurements
Cells (1–3 3 105 cells/well) were seeded in six-well plates, and conditioned
medium was collected at different times (0–24 hr). CXCL13 levels were
measured using either human or mouse CXCL13 ELISA kits (R&D Systems).
Adenoviral Infections
Infections with PKCε or LacZ (control) AdVs were done as previously
described (Benavides et al., 2011; Meshki et al., 2010).
Cell Proliferation, Colony Formation, Migration, and In Vivo
Tumorigenesis Assays
These assays are described elsewhere (Caino et al., 2012a, 2012b). For
detailed information, see Supplemental Experimental Procedures.
Microarray and Data Mining Analysis
Total RNAwas obtained using themiRNeasy Mini Kit (QIAGEN). Detailed infor-
mation on microarrays, software, and databases used for bioinformatics are
presented in Supplemental Experimental Procedures.
Statistical Analysis
Data were analyzed using either a Student’s t test or ANOVA. p < 0.05 was
considered statistically significant.ACCESSION NUMBERS
The accession number for the raw and preprocessed datasets reported in this
paper is GEO: GSE86257.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
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